The second of two phase 3 studies evaluating NOV03 as a first-in-class investigational drug for treatment of signs and symptoms of dry eye disease associated with meibomian gland dysfunction has been initiated.
The first phase 3 study is at 85% enrollment, according to a press release from Bausch Health.
In a phase 2 study, the proprietary NOV03 (perfluorohexyloctane) solution met its primary efficacy endpoint, a statistically significant improvement in total corneal fluorescein staining compared with controls at 8 weeks.
NOV03, which includes no water or preservatives, also improved the
Uncategorized